CTOs on the Move

Adhezion Biomedical

www.adhezion.com

 
Adhezion Biomedical is a Hudson, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.adhezion.com
  • 506 Pine Mountain Rd
    Hudson, NC USA 28638
  • Phone: 828.728.6116

Executives

Name Title Contact Details

Similar Companies

WR Medical

WR Medical is a Stillwater, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bleep Sleep

Fewer than 50% of Sleep Apnea patients stick with a CPAP solution – including us. So we decided to do something about it. Not sleeping sucks. Not sleeping and spending a fortune on CPAP devices that leak, fall off or leave marks on your face sucks even worse. That`s why we invented the DreamPort Sleep Solution – the world`s first-ever maskless CPAP device. The result is the smallest, lightest, most ergonomically accommodating CPAP solution on the market – a device that fits comfortably and doesn`t restrict your movement – enabling patients to get a better night`s sleep. Our goal is simple – to make the best bleeping CPAP products on the planet. We won`t stop until every sleep apnea patient is sleeping like a baby.

Hammill Manufacturing

Hammill Manufacturing is a Maumee, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TranS1

Restructured under new ownership in 2015, TranS1 has emerged stronger than ever – ready to support a product line that provides a foundation for living well, driven by surgeon innovation. Our impressive team includes experienced R&D, Sales and Professional Education professionals. The TranS1 team is focused on resilient and continuous training of its sales force and physician customers, employing best in class training methods that ultimately benefit patients.

Procyrion

Procyrion is developing the first catheter-deployed circulatory assist device intended for long-term use. The Procyrion device will be the first minimally invasive tool for cardiologists to treat over 1M NYHA Class III and early class IV heart failure (HF) patients in the US who have few therapeutic options. In partnership with Texas Heart Institute, Procyrion is currently conducting preclinical testing of the Procyrion device.